Participated · Series A · Dec 2024

Abselion develops automated analytical instrumentation, notably its Amperia benchtop system, to simplify at-line protein analytics for biologics development and production. The company’s RED (redox-electrochemical-detection) technology enables sensitive, specific measurement of antibodies, AAVs and other proteins directly from crude samples, producing results in as little as one minute. Abselion positions the Amperia to deliver on-the-spot process insights that improve efficiency and accuracy in life‑science research and bioprocessing. The product targets applications across development and production workflows for biologics such as antibodies and viral vectors. The company is led by CEO Ruizhi Wang and is based in Cambridge, UK. Recent fundraising is intended to support commercialisation and to expand the Amperia system’s capabilities. HexagonFab is a University of Cambridge spin-out that develops affordable, convenient analytical lab instruments to simplify biomolecular interaction analysis for pharma research and manufacturing. Its first product, the Bolt, is a handheld device that uses electrical detection with a graphene-based semiconductor sensor to measure protein, antibody and small-molecule affinity and kinetics down to low nanomolar concentrations. The Bolt provides real-time signals, requires no installation, and delivers results in hours rather than days, enabling on-site testing by researchers and manufacturing quality-control teams. HexagonFab positions the Bolt to reduce costs, delays and failures in biopharmaceutical discovery and production, accelerating development of novel medicines for small patient populations. Proceeds from the seed round will be used to grow the team, complete development of the Bolt, and launch the product commercially. The company describes its instruments as convenient, accessible and affordable for scientists, researchers, and drug manufacturers.